相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer
Danilo Rocco et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study
M. Dietel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study
Christos Chouaid et al.
LUNG CANCER (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
Hidenobu Ishii et al.
ONCOTARGET (2017)
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto et al.
DIAGNOSTIC PATHOLOGY (2016)
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
Jong-Mu Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
Steffen Filskov Sorensen et al.
TRANSLATIONAL ONCOLOGY (2016)
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
Wei Pan et al.
ONCOTARGET (2016)
The Danish Lung Cancer Registry
Erik Jakobsen et al.
CLINICAL EPIDEMIOLOGY (2016)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Jie Zhang et al.
THORACIC CANCER (2015)
The Danish National Patient Registry: a review of content, data quality, and research potential
Morten Schmidt et al.
CLINICAL EPIDEMIOLOGY (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
Roberta De Angelis et al.
LANCET ONCOLOGY (2014)
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
Yang Zhang et al.
ONCOTARGETS AND THERAPY (2014)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
A. K. Rud et al.
BRITISH JOURNAL OF CANCER (2013)
Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A. Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
Zhen Zeng et al.
PLOS ONE (2011)
The Danish Cancer Registry
Marianne Lundkjaer Gjerstorff
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Kenichi Suda et al.
Journal of Thoracic Oncology (2010)
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank
Erichsen
Clinical Epidemiology (2010)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Adjuvant chemotherapy in completely resected non-small-cell lung cancer
KMW Pisters et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
